Betahistine Dosing and Evidence‑Based Recommendations for Ménière’s Disease and Vestibular Disorders

Dosing Regimens

• The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) guideline notes that betahistine has been studied at 48 mg/day (24 mg twice daily) and 144 mg/day (48 mg three times daily) for Ménière’s disease; both regimens failed to show superiority over placebo in reducing vertigo attacks in the high‑quality BEMED randomized trial. Evidence level: high (rigorous double‑blind RCT). 1

• The AAO‑HNS guideline lists the same low‑dose (48 mg/day) and high‑dose (144 mg/day) regimens as the standard dosing options for Ménière’s disease. Evidence level: moderate (guideline consensus based on trial data). 1, 2

Treatment Duration

• Clinical trials have used a minimum trial period of 2–12 weeks to assess efficacy of betahistine for most vestibular conditions. Evidence level: moderate (guideline recommendation). 2, 3

• Extended treatment up to 9 months has been evaluated in clinical studies without demonstrating added benefit over placebo. Evidence level: moderate (guideline recommendation). 1, 2

Contraindications and Cautions

• Absolute contraindication: pheochromocytoma. Evidence level: high (guideline safety statement). 2, 3, 4

• Use with caution in patients with asthma or a history of peptic ulcer disease. Evidence level: high. 2, 3, 4

• Relative contraindications include renal or cardiac disease when betahistine is considered as part of a broader therapeutic strategy. Evidence level: moderate. 1

Safety Profile

• Betahistine is generally well‑tolerated, with serious adverse events being rare. Evidence level: high. 2, 3

• Common adverse effects (typically mild) comprise headache, balance disturbance, nausea, nasopharyngitis, sensation of warmth, eye irritation, palpitations, and upper gastrointestinal symptoms. Evidence level: high. 2, 4

Monitoring

• Patients should be reassessed as often as clinically warranted to evaluate symptom improvement, disease stabilization, medication intolerance, or side‑effects. Evidence level: high. 2, 4

Evidence Summary and Guideline Position

• The AAO‑HNS guideline states that, based on the BEMED trial, it cannot make a definitive recommendation on betahistine for controlling Ménière’s disease symptoms. Evidence level: high. 1

• Nevertheless, the guideline offers betahistine as an option for maintenance therapy, emphasizing variable patient responses and a favorable safety profile that may justify a trial of 48–144 mg/day for 2–3 months. Evidence level: moderate. 5

• The BEMED trial is highlighted as the best available evidence, contradicting earlier meta‑analyses that suggested benefit. Evidence level: high. 1

• A Cochrane systematic review reported a 56 % reduction in vertigo attacks with betahistine versus placebo, but the authors cautioned that the underlying studies were of low quality, limiting confidence in this estimate. Evidence level: low. 2, 3

Management of Dizziness When Betahistine + Cinnarizine Fail

Evidence on Betahistine Efficacy

• The high‑quality BEMED randomized trial found that betahistine (both 48 mg/day and 144 mg/day) did not reduce the frequency of vertigo attacks over 9 months compared with placebo in patients with Ménière’s disease, indicating no therapeutic benefit (Level I evidence). 6
• The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) guideline states that, because of the BEMED results, it cannot issue a definitive recommendation for betahistine in controlling Ménière’s disease symptoms (insufficient evidence). 6

Diagnostic Re‑evaluation Priorities

• Ménière’s disease is characterized by episodic vertigo accompanied by hearing loss, tinnitus, and aural fullness; confirming this phenotype is essential before proceeding to invasive therapy. 6
• Central vestibular causes—including stroke, multiple sclerosis, and vestibular migraine—must be excluded when dizziness persists after medication trials. 6

Evidence‑Based Treatments for Confirmed Ménière’s Disease

• Intratympanic steroid injections are recommended for patients with active Ménière’s disease who have not responded to non‑invasive measures; evidence from AAO‑HNS‑endorsed studies supports their use (moderate‑quality evidence). 7
• Positive‑pressure therapy (Meniett device) has been shown in systematic reviews to provide no statistically significant advantage over placebo for vertigo control, making it a lower‑priority option (low‑quality evidence). 7
• Oral corticosteroids have demonstrated overall improvement in vertigo in small pilot studies, but the data are limited and derived from low‑quality evidence. 6

Safety and Contra‑Indications for Betahistine

• Betahistine should be used with caution in patients with asthma or peptic‑ulcer disease and is contra‑indicated in pheochromocytoma, as highlighted by AAO‑HNS safety guidance (strong recommendation). 6

Clinical Practice Recommendations (AAO‑HNS)

• Discontinue betahistine and cinnarizine after a 2–3‑month trial if no clinically meaningful improvement is observed; continuing ineffective therapy is discouraged by high‑quality evidence from the BEMED trial. 6
• Re‑assess patients regularly for symptom change, medication intolerance, or adverse effects rather than waiting several months without evaluation; this recommendation is supported by guideline consensus (moderate evidence). 6
• Do not assume all dizziness is Ménière’s disease; a thorough differential diagnosis is required because many vestibular disorders mimic its presentation (guideline‑based recommendation). 6